Eli Lilly and Company, (NYSE: LLY) has named Dr. Thomas J. Fuchs as its first Chief Artificial Intelligence Officer. Fuchs will lead AI initiatives across the organization, including drug discovery, clinical trials, manufacturing, and commercial activities. His role will focus on leveraging AI and machine learning to enhance the development of new medicines and improve patient outcomes globally.
Fuchs brings a wealth of experience, previously serving as Dean and Chair of AI and Human Health at Mount Sinai and holding roles at Memorial Sloan Kettering, NASA, and Caltech. He is also the founder of Paige AI and holds advanced degrees in machine learning and technical mathematics.
Diogo Rau, Lilly’s EVP and Chief Information and Digital Officer, highlighted Fuchs’ potential to drive AI innovations that could revolutionize healthcare. Fuchs expressed his excitement about joining Lilly. He shared, “Throughout my career, I have focused on leveraging technology to help patients and enhance human health. Joining Lilly will allow me to expand this mission worldwide on an amazing scale. Building AI to benefit millions of patients is profoundly humbling.”
CIOs on the Move is brought to you by CIO Partners®. When hiring your next technology executive, experience matters. Trust CIO Partners, the #1 executive search firm for technology leadership talent.
